Contact Us
Drug Search Results
More Filters [+]

Oritavancin

Alternative Names: oritavancin, kimyrsa, orbactiv
Latest Update: 2024-12-05
Latest Update Note: Clinical Trial Update

Product Description

Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria.  (Sourced from: https://www.nejm.org/doi/full/10.1056/nejmoa1310422)

Mechanisms of Action: Cell Wall Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Jordan | Latvia | Lithuania | Poland | Portugal | Saudi Arabia | Slovakia | Spain | Sweden | Switzerland | United Kingdom | United States

Approved Indications: Gram-Positive Bacterial Infections | Gram-Positive Bacterial Infections

Known Adverse Events: Headache | Pruritus | Abscess | Chills | Diarrhea

Company: Melinta
Company Location: MORRISTOWN NJ 07963
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oritavancin

Countries in Clinic: Bulgaria, Greece, Latvia, Lithuania, Poland, Portugal, Romania, Spain, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Skin Diseases, Bacterial

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2022-001297-63

P2

Active, not recruiting

Unknown

2026-04-05

ML-ORI-201

P2

Unknown Status

Unknown

2025-06-30

ML-ORI-201

P2

Recruiting

Skin Diseases, Bacterial

2025-06-15

Recent News Events

Date

Type

Title

12/02/2024

News Article

 Melinta Joins NHIA Future of Infusion Advisory Council

10/16/2024

News Article

 Melinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta's Portfolio of Commercial and Investigational Stage Products

09/05/2024

News Article

 Melinta Therapeutics Announces the Appointment of Sunitha Lakshminarayanan, as Chief Technology Officer

08/06/2024

News Article

 Melinta Therapeutics Announces the Appointment of Fabrizio Tondolo, MD, as Vice President of Medical Affairs

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions